Several important questions about the relative safety and efficacy of apixaban versus warfarin in patients with nonvalvular atrial fibrillation have been answered.
At 11:54 a.m. on August 28 in Paris (5:54 a.m. U.S. east coast time), I can almost imagine a huge drop in cell phone call volume as the ARISTOTLE presentation begins at ESC. The ESC exposition site is right next to Charles de Gaulle airport. Will a temporary “no fly zone” be declared? We know…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
The possibilities — and the limits — of giving medical advice online
Our panel responds to the what the cessation of the PALLAS trial means for dronedarone. Will you still use this drug?
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M. I have said that the best tool for treating atrial fibrillation (AF) is education. I still strongly believe that, perhaps more than ever. AF presents itself to people in so many different ways…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
In the Women’s Health Study, which followed nearly 35,000 women for more than 15 years, mortality was significantly higher in the 1011 women who developed AF than in the women who did not, according to a report by David Conen and colleagues published in JAMA. Here are the incidence rates (per 1000 person-years of follow-up)…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
Results from EMPHASIS-HF (Eplerenone and Atrial Fibrillation in Patients with Systolic Heart Failure and Mild Symptoms) previously showed that adding the aldosterone antagonist eplerenone to standard therapy in patients with NYHA class II heart failure resulted in the reduction of the composite endpoint of death from cardiovascular causes or hospitalization for heart failure. Now, a…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
John Mandrola is a cardiac electrophysiologist and blogger on matters medical and general. Here is a recent post from his blog, Dr John M. Today, I would like to tell you about the most effective way to treat the most common heart ailment — atrial fibrillation (AF). It’s not the novel new blood-thinner, dabigatran (Pradaxa)….
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
In a series of blog posts on CardioExchange, Samuel Goldhaber, Director of the Venous Thromboembolism Research Group in the Cardiovascular Division at Brigham and Women’s Hospital, has been guiding us on best practices around dabigatran. Recently, he teamed up with Elaine Hylek, Director of the Thrombosis and Anticoagulation Service at Boston University School of Medicine,…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
The angiotensin-receptor blocker irbesartan does not significantly reduce cardiovascular events in patients with atrial fibrillation, according to the results of the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE I), published in the New England Journal of Medicine. Participants had been previously randomized in the ACTIVE A trial or the ACTIVE W trial. More than…
This content is exclusive to CardioExchange. To continue reading, please log in or request an invitation.
